An open label randomised controlled trial investigating the effect of donepezil on regional cerebral blood flow in adults with aneurysmal subarachnoid haemorrhage. - Donepezil in Aneurysmal Subarachnoid Haemorrhage (DASH) Trial

St George's University of London0 个研究点开始时间: 2013年7月1日最近更新: 2017年4月3日

适应症

试验速览

暂无简介。

•1. Patients aged 18-85 admitted to St George's Hospital neurosurgical service with confirmed aneurysmal subarachnoid haemorrhage (brain bleeding from an aneurysm).
•2. Amount of blood: Fisher score = 2 or greater (blood load on CT scan)
•3. Able to be enroled within 12-72 hours of brain bleeding symptom onset.
•4. Index aneurysm suitable for endovascular occlusion (coiling)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 76
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 24

•1. Allergy to donepezil or other piperidine derivatives.
•2. Pregnancy.
•3. Lactating or breast feeding women
•4. Male or female participants that are unwilling to use an effective method of birth control (hormonal or barrier method of birth control; abstinence from time consent is signed until 6 weeks after the last dose of Donepezil
•5. Known dementia.
•6. Severe hepatic impairment (Child-Pugh Class C)
•7. Patients with ‘sick sinus syndrome’ or other supraventricular cardiac conduction conditions such as sino-atrial or atrioventricular block.
•8. Patients with a history of brittle asthma or obstructive pulmonary disease, requiring regular steroid (inhalers or tablet) for control.

发起方